Every day, new technologies pave the way for patients to live longer, healthier lives. The Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center—one of the world’s preeminent centers implementing the latest treatment advances for correcting abnormal heart rhythms, or arrhythmias—is on the forefront of many new technologies.
Recently, TCAI became the first facility in the nation to use the EnSite Precision™ cardiac mapping system to treat Ventricular Tachycardia (VT) and Supraventricular Tachycardia (SVT), conditions marked by an abnormally fast heart rhythm caused by improper electrical activity in the upper part of the heart—as well as Premature Ventricular Contraction (PVC), a condition involving extra heart beats that disrupt a normal heart rhythm.
The EnSite cardiac mapping system is a next-generation platform designed to provide automation, flexibility and accuracy for diagnostic mapping used in ablation procedures to treat patients with cardiac arrhythmias.
Amin Al-Ahmad, M.D., a cardiac electrophysiologist at TCAI, performed the first VT and SVT cases. Jason Zagrodzky, M.D., who is also an electrophysiologist at TCAI, performed the first PVC case.
Additionally, TCAI became the first facility in Texas to implant the new AMPLATZER™ Amulet™ Left Atrial Appendage Occluder to seal off the left atrial appendage (LAA)—a small appendage connected to the left atrium—in patients diagnosed with non-valvular Atrial Fibrillation (A Fib).
Rodney Horton, M.D., a cardiac electrophysiologist at TCAI, implanted the AMPLATZER Amulet occluder to reduce the risk of stroke in a patient suffering from non-valvular AF.
The AMPLATZER™ Amulet™ Left Atrial Appendage Occluder is currently being evaluated in the AMPLATZER Amulet U.S. IDE Clinical Trial.
KXAN News recently spoke with Dr. Horton about this new technology.
Photo courtesy of St. Jude Medical